Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,239.7
-13.4 (-0.41%)

 

  • STI Straits Times Index
    3,239.7
    -13.4 (-0.41%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,688.8
    -0.2 (-0.01%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,900.8
    -531.2 (-1.87%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,682.4
    -37.3 (-1.37%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,900.6
    -239.1 (-1.13%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,389.1
    -30.9 (-0.48%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,196.1
    -29.8 (-1.34%)
    Index delayed 20 minutes
  • XAO XAO
    6,148.6
    9.0 (0.15%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 896.6M
  • Value: 1,072.6M
  • Rise: 132
  • Fall: 201
  • Unch: 509

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
ThaiBev0.815+0.095
RHT HealthTrust0.038+0.007
Rex Intl0.090-0.003
Ezion0.044-0.001
Genting Sing1.080-0.020
SingTel2.990-0.040
StarHub1.670-0.230
Mirach Energy^0.138-0.004
Nico Steel^0.004-0.002
YZJ Shipbldg SGD1.400-0.020

World Indices

World Indices
Name Last Change
Nasdaq 7,472.4 +45.5
HSI 27,900.8 -531.2
HSCEI 10,937.3 -233.0
Jakarta 6,389.1 -30.9
Nikkei 225 20,900.6 -239.1
SSE Comp 2,682.4 -37.3
Shanghai A 2,809.1 -39.1
Shanghai B 280.8 -1.4
ShenZhen A 1,452.8 -9.8
ShenZhen B 916.5 -9.3
Taiwan W 10,064.8 -24.2
PSE Comp 0.0
KOSPI 2,196.1 -29.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Tianjin ZX USD TIANJIN ZHONG XIN PHARM GROUP
Quotes 10 Minutes Delayed. Updated at 15 Feb 2019 17:04
Last (USD): 0.905 Change: -0.020 High: 0.930 Remarks: -
Change (%): -2.16 Low: 0.905
Open 0.930 Yesterday's Close 0.925
Buy Price 0.905 Sell Price 0.915
Buy Volume ('000) 49.0 Sell Volume ('000) 13.1
Cumulative Volume ('000) 127.2 Cumulative Value 116,464
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 0.09498 Trailing EPS (USD) e 0.10676 NAV (USD) b 0.8893
PE a 9.528 Trailing PE f 8.477 Price / NAV b 1.0177
Dividend (USD) d 0.030680 Cash In Hand (USD) g 0.2296 Issued & Paid-up Shares c 200,000,000
Dividend Yield (%) d 3.390 Price / Cash In Hand g 3.942 Treasury Shares h -
Beta - 75 Daysi 0.704 R-Squared - 75 Days(%)i 15.98 Market Cap (M) 695.830
Beta - 500 Daysi 0.707 R-Squared - 500 Days (%)i 6.89 Enterprise Value (M) 569.860
Piotroski F Score 7 Exchange Code T14 Par Value ( RMB ) 1.00000
52 Weeks Volatility (%) 30.1556 6-Month VWAP 0.933 Free Float (%) 92.4
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Pharmaceuticals: Other
Category Classification China / Medical & Biotechnology
Index Components FTSE ST All-Share Index / FTSE ST China Index / FTSE ST Fledgling Index / FTSE ST Health Care Index / FTSE ST Small Cap Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 25 Jun 2018.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Tianjin ZX USD SGX 695.830 9.528 8.477 1.0177 3.390
Industry China SGX 635.469 15.958 15.254 0.7858 3.450
Medical & Biotechnology SGX 1,106.022 26.392 28.770 1.4266 1.738
Pharmaceuticals: Other SGX 539.629 12.853 11.261 1.1441 2.965
Index FTSE ST All-Share Index SGX 5,471.733 12.471 14.663 1.2448 3.230
FTSE ST China Index SGX 3,378.298 5.409 6.652 0.6461 3.558
FTSE ST Fledgling Index SGX 86.915 32.994 22.861 0.6945 2.956
FTSE ST Health Care Index SGX 925.981 18.034 17.752 2.1875 2.232
FTSE ST Small Cap Index SGX 671.815 343.984 15.463 0.9805 6.258
Local Peer IX Biopharma SGX 135.365 - - 8.5714 -
Global Peer BAUSCH HEALTH COMPANIES INC NYSE 8,902.181 3.703 - 2.5664 -
Global Peer FOSUN PHARMA HKEx 64,845.443 17.999 19.253 1.9986 1.770
Global Peer ICON NASDAQ 7,895.942 28.051 25.837 5.9169 -
Global Peer JAZZ PHARMACEUTICALS PLC NASDAQ 7,596.349 15.571 14.613 2.5093 -
Global Peer SAGE THERAPEUTICS INC NASDAQ 7,545.525 - - 7.6333 -
Global Peer PERRIGO COMPANY PLC NYSE 6,650.200 55.604 54.199 1.1750 1.355
Global Peer SH PHARMA HKEx 50,305.046 12.392 10.006 1.1477 2.465
Global Peer CATALENT INC NYSE 6,120.955 73.217 44.908 3.9161 -
Global Peer Kalbe Farma Tbk. IDX 73,828,282.500 30.716 30.399 5.2985 1.587
Global Peer UNITED THERAPEUTICS CORP NASDAQ 5,214.313 12.477 9.605 1.9364 -
Other Global Peers AMARIN CORP ADR EACH REP 1 ORD GBP0.50 (NASDAQ), ARGENX SE SPON ADR EACH REP 1 ORD SHS (NASDAQ), GW PHARMACEUTICALS ADS EA REPR 12 ORD GBP0.00 (NASDAQ), HORIZON PHARMA PLC (NASDAQ), CRONOS GROUP INC (NASDAQ), INTERCEPT PHARMACEUTICALS INC (NASDAQ), LUYE PHARMA (HKEx), SSY GROUP (HKEx), LIVZON PHARMA (HKEx), ENDO INTERNATIONAL PLC (NASDAQ), IRONWOOD PHARMACEUTICALS INC (NASDAQ), AURORA CANNABIS INC (NYSE), MADRIGAL PHARMACEUTICALS INC (NASDAQ), PORTOLA PHARMACEUTICALS INC (NASDAQ), SUPERNUS PHARMACEUTICALS INC (NASDAQ), HEC PHARM (HKEx), SIHUAN PHARM (HKEx), ZOGENIX INC (NASDAQ), AERIE PHARMACEUTICALS INC (NASDAQ), MEDICINES CO (NASDAQ), MALLINCKRODT PLC (NYSE), MYOKARDIA INC (NASDAQ), TONG REN TANG (HKEx), PACIRA PHARMACEUTICALS INC (NASDAQ), THERAVANCE BIOPHARMA INC (NASDAQ), BLACKMORES LTD (ASX), INNOVIVA INC (NASDAQ), PRESTIGE CONSUMER HEALTHCARE INC (NYSE), CORCEPT THERAPEUTICS INC (NASDAQ), Kimia Farma Tbk. (IDX), HEXO CORP (NYSE American), AMPHASTAR PHARMACEUTICALS INC (NASDAQ), Indofarma Tbk. (IDX), INTERSECT ENT INC (NASDAQ), MEGA (SET), APHRIA INC (NYSE), CLINUVEL PHARMACEUTICALS LTD (ASX), REVANCE THERAPEUTICS INC (NASDAQ), ANI PHARMACEUTICALS INC (NASDAQ), CONSUN PHARMA (HKEx), EAGLE PHARMACEUTICALS INC (NASDAQ), ASSEMBLY BIOSCIENCES INC (NASDAQ), Tempo Scan Pacific Tbk. (IDX), FUDANZHANGJIANG (HKEx), ANIKA THERAPEUTICS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), OSIRIS THERAPEUTICS INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), COLLEGIUM PHARMACEUTICAL INC (NASDAQ), MEI PHARMA INC (NASDAQ), ARQULE INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), BIODELIVERY SCIENCES INTERNATIONAL (NASDAQ), SHANDONG XINHUA (HKEx), ALBIREO PHARMA INC (NASDAQ), ELIXINOL GLOBAL LTD (ASX), ACLARIS THERAPEUTICS INC (NASDAQ), ADAMAS PHARMACEUTICALS INC (NASDAQ), CATALYST PHARMACEUTICALS INC (NASDAQ), AXSOME THERAPEUTICS INC (NASDAQ), INTEC PHARMA LTD (NASDAQ), CELYAD ADS EACH REPR 1 ORD (NASDAQ), ACELRX PHARMACEUTICALS INC (NASDAQ), CERECOR INC (NASDAQ), MARINUS PHARMACEUTICALS INC (NASDAQ), FOAMIX PHARMACEUTICALS LTD (NASDAQ), OCI INTL (HKEx), DOD (SET), OASMIA PHARMACEUTICAL AB ADR EACH REP 3 ORD SHS (NASDAQ), GALMED PHARMACEUTICALS LTD (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), HARROW HEALTH INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), SANAI HEALTH GP (HKEx), OPTHEA LIMITED (ASX), MEDIWOUND LTD (NASDAQ), DURECT CORP (NASDAQ), NEOS THERAPEUTICS INC (NASDAQ), GOLDEN THROAT (HKEx), YSPSAH (Bursa), ZYNERBA PHARMACEUTICALS INC (NASDAQ), CUMBERLAND PHARMACEUTICALS INC (NASDAQ), VERONA PHARMA SPON ADR EACH REP 8 ORD SHS (NASDAQ), MELINTA THERAPEUTICS INC (NASDAQ), SYNERGY PHARMACEUTICALS INC DEL (NASDAQ), PHARMAXIS (ASX), JILIN CHANGLONG (HKEx), INVION LTD (ASX), SCYNEXIS INC (NASDAQ), TETRAPHASE PHARMACEUTICALS INC (NASDAQ), TIANDA PHARMA (HKEx), KEMPHARM INC (NASDAQ), BIOLINE RX LTD SPON ADS EACH REPR 10 ORD SHS (NASDAQ), EAGLE HEALTH HOLDINGS LTD (ASX), ORAMED PHARMACEUTICALS INC (NASDAQ), ALTHEA GROUP HOLDINGS LTD (ASX), CTI BIOPHARMA CORP (NASDAQ), VIVUS INC (NASDAQ), EVOKE PHARMA INC (NASDAQ), THC GLOBAL GROUP LTD (ASX), ACASTI PHARMA INC (NASDAQ), BOTANIX PHARMACEUTICALS LTD (ASX), LANSEN PHARMA (HKEx), ACHAOGEN INC (NASDAQ), PLX PHARMA INC (NASDAQ), AMPIO PHARMACEUTICALS INC (NYSE American), COGSTATE (ASX), AGILE THERAPEUTICS (NASDAQ), LIPOCINE INC (NASDAQ), VITA LIFE SCIENCES LIMITED (ASX), IDT AUSTRALIA LIMITED (ASX), C HEALTH GP (HKEx), ACRUX (ASX), CYTRX CORP (NASDAQ), EYEGATE PHARMACEUTICALS INC (NASDAQ), PAIN THERAPEUTICS (NASDAQ), PERNIX THERAPEUTICS HOLDINGS INC (NASDAQ), MY SIZE INC (NASDAQ), BAYTACARE PHARM (HKEx), MYOS RENS TECHNOLOGY INC (NASDAQ), ANTISENSE THERAPEUTICS (ASX), REGULUS THERAPEUTICS INC (NASDAQ), CANNPAL ANIMAL THERAPEUTICS LTD (ASX), Pyridam Farma Tbk (IDX), PHARMAUST LIMITED (ASX), FLEX PHARMA INC (NASDAQ), SONOMA PHARMACEUTICALS INC (NASDAQ), TONIX PHARMACEUTICALS HLDG CORP (NASDAQ), CONTRAVIR PHARMACEUTICALS INC (NASDAQ), RITTER PHARMACEUTICALS INC (NASDAQ), HUA HAN HEALTH (HKEx), C ANIMAL HEALTH (HKEx), LONGRUN TEA (HKEx)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.020
+2.26 %
10 Days -+0.035
+4.02 %
20 Days -+0.035
+4.02 %
Medium Term Return 3 Months -+0.020
+2.26 %
6 Months --0.135
-12.98 %
1 Year 0.030-0.030-
Long Term Return 2 Years 0.052-0.045
+0.74 %
3 Years 0.089-0.010
+8.63 %
5 Years 0.122-0.070
+5.33 %
Annualised Return Annualised --
+1.04 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.805 - 1.290 Change From 1 Year Low +0.100 % Change From 1 Year Low (%) +12.42
Change From 1 Year High -0.385 % Change From 1 Year High (%) -29.84
2 Years Range 0.805 - 1.290 Change From 2 Years Low +0.100 % Change From 2 Years Low (%) +12.42
Change From 2 Years High -0.385 % Change From 2 Years High (%) -29.84
5 Years Range 0.730 - 1.915 Change From 5 Years Low +0.175 % Change From 5 Years Low (%) +23.97
Change From 5 Years High -1.010 % Change From 5 Years High (%) -52.74
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

In the 1950s, with the China government's policy of merging state-owned pharmaceutical enterprises with the private sector, Tianjin Municipal Chinese Medicinal Materials Corpn (TMCM) merged and reorganised the various factories and stores in Tianjin. In December 1992, TMCM was converted from a state-owned enterprise to a company limited by shares whereby shares were issued to legal persons and its employees. In connection therewith, it was renamed Tianjin Traditional Chinese Medicine Group Co Ltd (TTCM). Following the corporatisation of the Company, the shares issued to the employees were traded at the Tianjin Securities Trading Centre.In conjunction with the proposed public offering, TTCM adopted its present name. Pursuant to the restructuring, it became the holding company for the Group.The Group's businesses cover a wide range of products including Chinese patent medicine, Chinese medicinal drinks, Chinese medicinal raw materials, biotechnology medicine, chemical raw material medicine and preparations, and nutritional and health products. It has over 800 medicinal products in over 20 types of formulations. The main products are Suxiao Jiuxin pill (used for treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment of intestines and stomach disease), Gengnian An (used for treatment of menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu Zhuyu capsule (used for treatment of diseases relating to heart and head blood vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of diabetes), and Te Zi She Fu (used for diminishing inflammation).The holding company and ultimate holding company is Tianjin Pharmaceutical Hldgs, a company incorporated in Tianjin, China.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2017 Dec 2017 Part 1(3.65 MB)
Annual Report 2016 Dec 2016 Part 1(2.98 MB)
Annual Report 2015 Dec 2015 Part 1(2.25 MB)
Annual Report 2014 Dec 2014 Part 1(2.46 MB)
Annual Report 2013 Dec 2013 Part 1(1.87 MB)
Part 2(0.02 MB)
Part 3(0.02 MB)
Annual Report 2012 Dec 2012 Part 1(9.46 MB)
Annual Report 2011 Dec 2011 Part 1(11.18 MB)
Annual Report 2010 Dec 2010 Part 1(5.33 MB)
Annual Report 2009 Dec 2009 Part 1(0.75 MB)
Annual Report 2008 Dec 2008 Part 1(2.38 MB)
Annual Report 2007 Dec 2007 Part 1(1.33 MB)
Annual Report 2006 Dec 2006 Part 1(5.41 MB)
Annual Report 2005 Dec 2005 Part 1(0.68 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
15 Feb 2019 0.930 0.930 0.905 0.905 127,200 0.9156
14 Feb 2019 0.930 0.930 0.915 0.925 313,400 0.9238
13 Feb 2019 0.920 0.930 0.910 0.930 478,600 0.9195
12 Feb 2019 0.885 0.915 0.885 0.910 637,900 0.9055
11 Feb 2019 0.890 0.890 0.875 0.880 254,100 0.8806
08 Feb 2019 0.865 0.895 0.850 0.885 424,000 0.8753
07 Feb 2019 0.865 0.875 0.865 0.875 53,600 0.8666
04 Feb 2019 0.860 0.865 0.855 0.855 45,900 0.8591
01 Feb 2019 0.850 0.870 0.850 0.870 272,600 0.8585
31 Jan 2019 0.845 0.860 0.830 0.855 292,900 0.8444
30 Jan 2019 0.830 0.850 0.830 0.835 210,900 0.8430
29 Jan 2019 0.820 0.840 0.820 0.830 110,800 0.8337
28 Jan 2019 0.840 0.855 0.830 0.835 362,600 0.8384
25 Jan 2019 0.850 0.860 0.840 0.845 231,000 0.8461
24 Jan 2019 0.865 0.870 0.845 0.850 277,900 0.8553
23 Jan 2019 0.860 0.870 0.860 0.860 9,700 0.8658
22 Jan 2019 0.875 0.880 0.870 0.870 43,600 0.8717
21 Jan 2019 0.875 0.885 0.875 0.875 156,700 0.8780
18 Jan 2019 0.885 0.885 0.870 0.870 166,700 0.8797
17 Jan 2019 0.875 0.885 0.870 0.875 307,500 0.8776
16 Jan 2019 0.890 0.890 0.860 0.865 412,200 0.8681
15 Jan 2019 0.860 0.890 0.860 0.885 151,300 0.8762
Summary
Current 2 Weeks
(31 Jan 2019 to 15 Feb 2019)
0.845 0.930 0.830 0.905 2,900,200 -
Previous 2 Weeks
(17 Jan 2019 to 30 Jan 2019)
0.875 0.930 0.830 0.835 1,877,400 -
4 Weeks from
(18 Dec 2018 to 16 Jan 2019)
0.875 0.930 0.830 0.865 3,162,300 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.